GlassScriptPhysician profile
Homayoon Akbari
NPI 1205831229
$432.19
in general payments reported to CMS, 2019-2025
13 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.38 · 2021: $53.76 · 2022: $69.19 · 2023: $55.82 · 2024: $62.40 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioprotect Medical, INC. | $125.64 | 2025 | Bioprotect Balloon Implant System |
| Innocoll Pharmaceuticals Limited | $70.53 | 2021-2022 | |
| Integra Lifesciences Corporation | $39.95 | 2021-2022 | |
| Davol INC. | $36.07 | 2023 | |
| Depuy Synthes Sales INC. | $23.75 | 2024 | Xcm Biologic Tissue Matrix |
| Lemaitre Vascular, INC. | $23.10 | 2024 | Artegraft Vascular Graft |
| Checkpoint Surgical, INC | $19.75 | 2023 | Checkpoint Stimulators |
| Kerecis Limited | $19.51 | 2019 | |
| Teleflex LLC | $17.27 | 2019 | |
| Innovation Technologies INC | $15.55 | 2024 | Irrisept |
| Acell, INC. | $15.26 | 2019 | |
| Misonix INC | $13.34 | 2019 | |
| Thd America, INC. | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Homayoon Akbari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.